Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;3(2):169-77.
doi: 10.1007/s13555-013-0040-z. Epub 2013 Dec 13.

The costs of psoriasis medications

Anssi Mustonen  1 , Kalle Mattila, Mauri Leino, Leena Koulu, Risto Tuominen
Affiliations

The costs of psoriasis medications

Anssi Mustonen et al. Dermatol Ther (Heidelb). 2013 Dec.

Abstract

Introduction: Psoriasis is a chronic disease, which contributes to the economic burden on health care. The distribution of psoriasis medication costs and the quality of life in these patients has been estimated to be around 20% of total costs.

Objectives: To estimate the economic distribution of medications and the impact of multiple treatment options on a patient's quality of life.

Materials and methods: The study was based on 236 Finnish psoriasis patients. The Finnish Social Insurance Institution had databases for all psoriasis related medications purchased. Each purchase, during the 1-year study period (1 October 2009-30 September 2010), was recorded and analyzed. The dermatological quality-of-life index was collected from the medical records.

Results: Total medication costs were <euro>1,083 per year per patient. Topical treatments were the most often purchased medication and they comprised 18% of the total medication costs. Ten percent of the patients needed 3 or more medication changes during the 1-year study period. Biologics were used only by 5% of patients, but they produced 67% of total medication costs. Patients needing various treatments had higher medication costs and a poorer quality of life.

Conclusion: A small number of patients generated a great sum of medication costs partly due to the need to change medications. These patients had the worst quality-of-life index scores. Biologics formed a major cost component.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The average costs of all medications and emollients as a function of the number of treatment options (only acitretin, ciclosporin, methotrexate, biologics, topical treatments and UV-phototherapy) received during the 1-year study period. The number of treatment options represents the number of different medications or UV therapy administered to the patient, with the percentage of patients in each group in parenthesis. Differences between all treatment groups were statistically significant (p < 0.05)
Fig. 2
Fig. 2
Dermatological Life Quality index (DLQI) values increased by the number of treatment options to the patient during the 1-year study period. A significant (p < 0.05) correlation (r = 0.384) existed between DLQI and the number of treatment options
See this image and copyright information in PMC

References

    1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001;15(1):16–17. doi: 10.1046/j.1468-3083.2001.00192.x. - DOI - PubMed
    1. Radtke MA, Augustin M. Economic considerations in psoriasis management. Clin Dermatol. 2008;26(5):424–431. doi: 10.1016/j.clindermatol.2007.10.024. - DOI - PubMed
    1. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573. - PubMed
    1. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol. 1996;35(12):1289–1291. doi: 10.1093/rheumatology/35.12.1289. - DOI - PubMed
    1. Lambert J, Dowlatshahi EA, de la Brassinne M, Nijsten T. A descriptive study of psoriasis characteristics, severity and impact among 3,269 patients: results of a Belgian cross sectional study (BELPSO) Eur J Dermatol. 2012;22(2):231–237. - PubMed

LinkOut - more resources